INLIGHT: A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

WVE-007 - Wave Life Sciences

Zepbound (tirzepatide) - Eli Lilly

INLIGHT: A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity (clinicaltrials.gov) - Oct 27, 2026 - P1/2 | N=400 | Recruiting | Sponsor: Wave Life Sciences USA, Inc. | N=296 ➔ 400
Enrollment change • Genetic Disorders • Obesity

http://clinicaltrials.gov/ct2/show/NCT06842186

Oct 27, 2026